<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="360">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01585675</url>
  </required_header>
  <id_info>
    <org_study_id>04-0688</org_study_id>
    <secondary_id>P50CA058187</secondary_id>
    <nct_id>NCT01585675</nct_id>
  </id_info>
  <brief_title>Specimen Banking From Patients With Lung Cancer</brief_title>
  <official_title>Specimen Banking From Patients With Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Federal Government</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the protocol is to develop a comprehensive specimen banking program
      from patients with lung cancer for future translation research, which will enable the
      investigators to detect lung cancer earlier, develop better therapies and explore screening
      and prevention strategies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aims of the study are as follows: 1) to continue to unravel the complex biology of lung
      cancer 2) to identify early detection and prognostic markers to guide therapeutic decision
      3) to define markers of response and/or resistance to drug therapy, and 4) to identify new
      therapeutic and prevention targets.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>The primary objective of the protocol is to develop a comprehensive specimen banking program from patients with lung cancer for future translational research.</measure>
    <time_frame>6 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>No statistical analysis will be applied to the overall collection of samples. Rather, each project that utilized tissue bank resources will require an appropriate statistical plan to be submitted along with the initial tissue request.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Lung Neoplasms</condition>
  <arm_group>
    <arm_group_label>Diagnosis/treatment of lung cancer</arm_group_label>
    <description>Specimen Banking</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tissue, blood, urine, and sputum, breath
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who are undergoing further testing for the diagnosis or treatment of lung cancer.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects who are undergoing further testing for the diagnosis or treatment of lung
             cancer.

          2. Oral and written informed consent

        Exclusion Criteria:

        1. Any individual who does not give oral and written consent for participation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wilbur Franklin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mary K. Jackson</last_name>
    <phone>303-724-1650</phone>
    <email>mary.k.jackson@ucdenver.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary K. Jackson</last_name>
      <phone>303-724-1650</phone>
      <email>mary.k.jackson@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Wilbur Franklin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 16, 2016</lastchanged_date>
  <firstreceived_date>April 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung Cancer</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
